Juarez M et al., 2020-06: Screening of 28 malignant cell lines at 5 micromolar ivermectin reporting breast and ovarian lines as most sensitive, G0-G1 arrest, synergy with docetaxel, cyclophosphamide and tamoxifen, preferential activity against stem-cell-enriched populations, and tumour shrinkage in mice.
Ivermectin reduced both cell viability and colony formation capacity in the stem cell-enriched population as compared with the parental one.
n/a (PubMed abstract)
Juarez M et al., 2020-06: Screening of 28 malignant cell lines at 5 micromolar ivermectin reporting breast and ovarian lines as most sensitive, G0-G1 arrest, synergy with docetaxel, cyclophosphamide and tamoxifen, preferential activity against stem-cell-enriched populations, and tumour shrinkage in mice. Study type: 28 cancer cell lines + tumour-bearing mice. N: 28 cell lines; mouse numbers not stated in the abstract. Country: Mexico (Instituto Nacional de Cancerologia, Mexico City). Dose: 5 uM in vitro; in vivo dose not stated in the abstract. Funder/COI: not stated in the PubMed record. Comparator: parental vs stem-cell-enriched populations; vehicle in mice; combination vs single cytotoxic drugs. Important for the exposure question because the group argues 5 uM is clinically feasible. Also filed as IVA-21 (claims C5, C6). Study type: animal.
